Tysabri Continues Comeback; On Pace To Reach 100,000 Patients In 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
The once-withdrawn MS drug continues to gain patients in the U.S. and EU, with an improving safety profile, Biogen says.
You may also be interested in...
Raptiva PML Case Brings Another REMS
FDA wants black-box warning, new safety plan for psoriasis drug.
Raptiva PML Case Brings Another REMS
FDA wants black-box warning, new safety plan for psoriasis drug.
Tysabri PML Cases Pose REMS Challenges To FDA
Two new cases of the brain infection could impact sales of the drug, particularly in the treatment naive multiple sclerosis setting.